SLC5A2 and diabetic kidney disease: Despite recent advances in nephroprotective therapies—including renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and non-steroidal mineralocorticoid receptor antagonists (MRAs)—these agents fail to reverse the substantial disease burden imposed by DKD [4].